Anti TNF- ? Tedavisi Altında Gelişen Büllöz Pemfigoid Olgusu

Objective & Hypothesis:Tumor necrosis factor-alpha (TNF-?) plays a crucial role in the development of autoimmune diseases, and anti-TNF-? agents are used in the treatment of this group of diseases.

📊

Key Findings & Data:However, some adverse events such as various autoimmune diseases can occur with use of these agents.

💡

Conclusion & Impact:In this report, we present a female case who was diagnosed as bullous pemphigoid while receiving adalimumab for rheumatoid arthritis

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Tumor necrosis factor-alpha (TNF-?) plays a crucial role in the development of autoimmune diseases, and anti-TNF-? agents are used in the treatment of this group of diseases. However, some adverse events such as various autoimmune diseases can occur with use of these agents. In this report, we present a female case who was diagnosed as bullous pemphigoid while receiving adalimumab for rheumatoid arthritis

Özet

Otoimmün inflamatuvar hastalıkların etiyopatojenezinde TNF?'nın önemli rolü olduğu ve tedavide anti-TNF-? ilaçların yıllardan beri kullanıldığı bilinmektedir. Bununla birlikte bu ilaçların kullanımı sırasında farklı otoimmün hastalıkların ortaya çıkması gibi istenmeyen sonuçlarla karşılaşılabilmektedir. Bu yazıda romatoid artrit tanısıyla adalimumab kullandığı dönemde büllöz pemfigoid tablosu gelişen bir kadın hasta anlatıldı ve tartışıldı

🔖

Cite This Article

ALTINDAĞ, Ö., AYDENİZ, A., GÜRSOY, S. (2010). Anti TNF- ? Tedavisi Altında Gelişen Büllöz Pemfigoid Olgusu. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 25 - Sayı: 4, 214–216. https://ajindex.com/articles/376146

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Patton T, Korman N. Role of methotrexate in the treatment of bullous pemphigoid in the elderly. Drug Aging 2008; 25: 623-9. Suárez-Fernández R, España-Alonso A, Herrero-González JE, Mascaró-Galy JM. [Practical management of the most common autoimmune bullous diseases]. Actas Dermosifiliogr 2008; 99: 441-55.
Kijima A, Inui S, Nakamura T, Itami S, Katayama I. Does drug- induced hypersensitivity syndrome elicit bullous pemphigoid? Allergol Int 2008 Jun; 57: 181-2.
Wozniak K, Kowalewski C, Hashimoto T, Ishii N, Glinska- Wielochowska M, Schwartz RA. Penicillin-induced anti-p200 pemphigoid: an unusual morphology. Acta Derm Venereol 2006; 86: 443-6.
Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006; 5: 562-4.
Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L. [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol 2003; 130 (2 Pt 1): 187-90.
Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006; 155: 330-6.
Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun 2008; 10: 344-58.
Kent PD, Davis JM III, Davis MD, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-8.
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. J Dermatol 2007; 156: 486-91.